Clinical trial NCT00728689: Phase I Trial of an Investigational Small Pox Medication
Official title: A Phase I Randomized, Double-Blind, Crossover, Exploratory Study of the Pharmacokinetics of a Single Oral Dose of Form I Versus Form V Capsules of the Anti-Orthopoxvirus Compound ST-246® in Fed Normal Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Orthopoxviral Disease
Smallpox
Monkey Pox
Keywords: Orthopoxviral
Smallpox
Monkey pox
Lead sponsor: SIGA Technologies
Sponsor class: INDUSTRY
Collaborators: name: National Institutes of Health (NIH)
First posted: 2008-08-06
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.

Detailed description: This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.

Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.

Eligibility criteria: Inclusion Criteria:

1. 18 to 50 years
2. Available for clinical follow-up duration of study.
3. Able/willing to give written consent.
4. Good general health; no clinically significant medical history.
5. Refrain from taking any medications from screening through 72 hours after last dose.
6. Adequate venous access.
7. PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
8. Meet Lab Criteria within 28 days prior to receipt of drug.
9. Negative pregnancy test
10. Non smokers
11. No alcohol or caffeine
12. Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study

Exclusion Criteria:

1. Marked baseline prolongation of QT/corrected QT interval (QTc) interval (
2. History of additional risk factors for Torsade de Pointes
3. Clinically significant abnormal ECG
4. Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval
5. Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.
6. History of any clinically significant conditions including:

   * Asthma
   * Diabetes mellitus
   * History of thyroidectomy or thyroid disease
   * Serious angioedema episodes
   * Head trauma resulting in a diagnosis of TBI other than concussion
   * Seizure or history of seizure
   * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
   * Malignancy
7. Family history of idiopathic seizures
8. History or presence of neutropenia or other blood dyscrasia
9. Known Hepatitis B or Hepatitis C infection
10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.
11. Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.
12. Known clinically significant chronic viral infection (or current clinically significant viral infection
13. History of frequent or severe headaches or migraines
14. Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection
15. Woman who is pregnant or is breast-feeding or planning to become pregnant
16. On any concomitant medications
17. History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.
18. Inability to swallow medication
19. Body Mass Index above 35 or below 18,
20. Current drug abuse or alcohol abuse.
21. Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice
22. Clinically significant lactose intolerance
23. Received experimental drug within 30 days
24. Vaccination within 30 days
25. Total of more than 350 milliliters (mL) of blood drawn in 2 months
26. Treatment with any immunosuppressant or immunomodulatory medication in 3 months
27. Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
28. History or diagnosis that would affect absorption of study medication

Primary outcomes:
measure: Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
timeFrame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
measure: Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
timeFrame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
measure: Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
timeFrame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
measure: Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
timeFrame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
measure: Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
timeFrame: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
Secondary outcomes:
measure: Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Orlando Clinical Research Center
state: Florida
Study officials:
affiliation: Orlando Clinical Research Center
name: Thomas C Marbury, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Ahmad S, Hasan H, Ahmad Suhaimi NA, Albakri KA, Abedalbaset Alzyoud A, Kadir R, Mohamud R. Comprehensive literature review of monkeypox. Emerg Microbes Infect. 2022 Dec;11(1):2600-2631. doi: 10.1080/22221751.2022.2132882.